HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Large Cell Carcinoma

A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Also Known As:
Carcinoma, Large Cell; Carcinomas, Large Cell; Cell Carcinoma, Large; Cell Carcinomas, Large; Large Cell Carcinomas
Networked: 483 relevant articles (7 outcomes, 44 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Squamous Cell Carcinoma (Epidermoid Carcinoma)
2. Adenocarcinoma
3. Small Cell Carcinoma
4. Carcinoma (Carcinomatosis)
5. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

Experts

1. Pelosi, Giuseppe: 4 articles (09/2015 - 04/2008)
2. Cavazza, Alberto: 4 articles (09/2014 - 12/2004)
3. Rossi, Giulio: 3 articles (06/2013 - 12/2004)
4. Scagliotti, Giorgio V: 3 articles (05/2012 - 05/2002)
5. Michiels, Stefan: 3 articles (01/2012 - 07/2004)
6. Delbaldo, Catherine: 3 articles (01/2012 - 07/2004)
7. Soria, Jean-Charles: 3 articles (01/2012 - 07/2004)
8. Syz, Nathalie: 3 articles (01/2012 - 07/2004)
9. Le Chevalier, Thierry: 3 articles (01/2012 - 07/2004)
10. Shen, Hong: 3 articles (09/2011 - 10/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Large Cell Carcinoma:
1. Cisplatin (Platino)FDA LinkGeneric
2. pemetrexed (MTA)FDA Link
05/01/2010 - "The guidance issued by NICE in September 2009 states that pemetrexed in combination with cisplatin is recommended as an option for the first-line treatment of patients with locally advanced or metastatic NSCLC only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma."
07/20/2008 - "Overall survival was statistically superior for cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with adenocarcinoma (n = 847; 12.6 v 10.9 months, respectively) and large-cell carcinoma histology (n = 153; 10.4 v 6.7 months, respectively). "
05/01/2012 - "In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. "
12/01/2009 - "Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma. "
11/01/2009 - "To estimate the cost-effectiveness of first-line cisplatin/pemetrexed (Cis/Pem) compared with cisplatin/gemcitabine (Cis/Gem), carboplatin/paclitaxel (Carb/Pac), and carboplatin/paclitaxel/bevacizumab (Carb/Pac/Bev) in patients with advanced non-small cell lung cancer (NSCLC), particularly in those with nonsquamous cell histology (i.e., adenocarcinoma, large cell carcinoma, or histology not otherwise specified). "
3. Adenocarcinoma of lungIBA
4. gemcitabineFDA Link
5. antigen CYFRA21.1IBA
6. Messenger RNA (mRNA)IBA
7. ParaffinIBA
8. Doxorubicin (Adriamycin)FDA LinkGeneric
9. Cyclophosphamide (Cytoxan)FDA LinkGeneric
10. Carboplatin (JM8)FDA LinkGeneric

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Combination Drug Therapy (Combination Chemotherapy)
3. Radiotherapy
4. Aftercare (After-Treatment)
5. Immunotherapy